Vivimed Labs Limited (NSE:VIVIMEDLAB): What Is Driving Margins?

With analysts expecting Vivimed Labs Limited (NSEI:VIVIMEDLAB) to reveal a fall in earnings of -16.80% over the next year, it's important to take a step back and consider this damaging sentiment. Investors should consider the forces that are pushing this decrease, as the return realised by shareholders may look different in the future if underlying assumptions are not realised. To help investors get a top level understanding, I will try to evaluate Vivimed Labs's margin behaviour to assist in analysing the revenue and cost anatomy behind the earnings expectations for the future and the impact it has on shareholder returns relative to the wider industry.

Check out our latest analysis for Vivimed Labs

What can we tell from VIVIMEDLAB's profit margin?

Attractive margins generally indicate a desirable ability to translate sales revenue in to earnings, and return for shareholders. Knowing the portion of top line revenue that is turned into net income helps to assess this ability whilst spotting profit drivers, and can be found by calculating VIVIMEDLAB's profit margin.

Vivimed Labs's margin has expanded in the past five years, due to a 19.20% average growth in net income exceeding average revenue growth of 12.08%, indicating that that the previous revenue growth has been acompanied by a growing portion translated in to earnings. The current 13.61% margin seems to continue this movement, which could imply improved cost efficiency as well as increasing revenue contributed to the previous earnings growth.

What can we tell from future expectations?

It is expected that margins will continue to expand, with 8.09% in expected annual revenue growth and 19.37% earnings growth expected annually. This suggests future earnings growth is driven further by enhanced cost efficiency alongside revenue increases, which is enlarging the incremental amount of net income that is retained from the forecasted revenue growth. Despite this, investors should realise a expanding margin can hold various implications on the company's performance depending on how it operates, which makes further research very important.

Profit margins are commonly useful when employed as a comparitive measure to judge a business' profit-making ability against its industry. For VIVIMEDLAB, it is expected that profit margins will expand simultaneously with margins in the Pharmaceuticals industry, whilst at the same time, VIVIMEDLAB’s forecasted ROE of 16.93% exceeds that of the expected 11.43% ROE of the industry (note that this observation is also influenced by relative debt levels). This suggests that analysts expect Vivimed Labs's return per dollar of equity will exceed the industry due to the earnings attributes identified in our margin analysis. But before moving forward, it must be remembered that bottom line earnings and profit margins are susceptible to being manipulated and don't always give the full picture. Thus, it is essential to run your own analysis on Vivimed Labs's future earnings whilst maintaining a watchful eye over the sustainability of their cost management methods and the runway for top line growth.

Next Steps:

For VIVIMEDLAB, I've compiled three important aspects you should look at:

1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
2. Valuation: What is VIVIMEDLAB worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether VIVIMEDLAB is currently mispriced by the market.
3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of VIVIMEDLAB? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.